Feline Rhinotracheitis-Calici-Panleukopenia Vaccine
Modified Live Virus

For use in cats only

**FELOCELL® 3**

**PRODUCT DESCRIPTION**
Felocell 3 is for vaccination of healthy cats as an aid in preventing feline viral rhinotracheitis (FVR) caused by feline herpesvirus-1, feline respiratory disease caused by feline calicivirus (FCV), and feline panleukopenia virus (FPV) caused by feline parvovirus (FPV). Felocell 3 is a combined vaccine containing live, attenuated viruses of Feline herpesvirus-1, calicivirus, and parvovirus strains. Live attenuated viruses of each of these viruses are packaged in a sterile freeze-dried form with inert gas in place of vacuum.

**SAFETY AND BRUISER:** Safety of Felocell 3 was demonstrated in field trials involving 2,288 cats. No serious postvaccination reactions attributable to the vaccine were reported.

**Efficacy of Felocell 3** was determined by challenge-of-immunity tests. Vaccinated cats experimentally exposed to severe challenge antigen were immunologically protected compared to nonvaccinated control cats after challenge with FCV, FPV, or REV. Efficacy of the FPV fraction of Felocell 3 was further established as ≥95% in a 3-year repeat antigenicity study. Three years after initial efficacy studies were conducted, FPV challenge tests were repeated. After challenge, all vaccinated cats remained clinically healthy while 80% of control cats developed clinical signs of FPL.

**Duration and character of the immune response to the viral antigens of Felocell 3** were determined in a multi-center serostudy involving 40 small animal veterinary clinics located in the United States (38) and Canada (2). Two hundred seventy-two male and female intact and neutered cats of various ages, breeds, weights, lifestyles and times since last vaccination were enrolled in the study. Cats were divided into three age groups: 0–12 months, 12–24 months, and ≥24 months. During the course of the study, serum neutralization antibody titers were monitored at 4, 8, 12, and 16 months after the last booster. All previously administered vaccines were Felocell CVR or Felocell CVR-C. A blood sample was collected from each cat and serum submitted to a single diagnostic laboratory, thus ensuring a standardized test methodology. All samples were analyzed according to standard procedures and methodology. As shown in the tables below, elevated geometric mean titers were maintained for ≥12 months after the last booster. Since the study was conducted under field conditions with clinical controls, it is possible that natural exposure to infective agents could have occurred without clinical signs of infection during the course of the study. In such cases, the titers measured in the study could be the result of exposure to the disease in addition to vaccination.

**Table 1. Geometric mean titer (GMT) of cats Time Since Last Vaccination (Months)**

<table>
<thead>
<tr>
<th>Antigen</th>
<th>0–12</th>
<th>12–24</th>
<th>≥24</th>
</tr>
</thead>
<tbody>
<tr>
<td>FPV</td>
<td>41/25</td>
<td>43/25</td>
<td>46/33</td>
</tr>
<tr>
<td>PCV</td>
<td>34/16</td>
<td>45/20</td>
<td>68/33</td>
</tr>
<tr>
<td>FCV</td>
<td>41/25</td>
<td>47/33</td>
<td>50/33</td>
</tr>
<tr>
<td>REV</td>
<td>31/16</td>
<td>36/20</td>
<td>43/33</td>
</tr>
</tbody>
</table>

**DIRECTIONS:**

**Vacination of pregnant queens should be avoided.** Contains gentamicin as preservative. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine. Vaccination of pregnant queens should be avoided. In case of anaphylaxis, administer epinephrine or equivalent.

**REFERENCES:**

This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are infected by an infectious disease, are immunosuppressed or otherwise compromised, are reinfected with the same infectious agent, are otherwise immunocompromised, or the vaccine is not administered in accordance with labeled directions.

**SHARE THIS**

**PRESERVATIONS:**
None.

**Storing:**
Store at 2°C–7°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze. Use entire contents when first opened.

**Sterilization:**
Sterilized and unopened packages should be used if administration of the vaccine is delayed. Expect a sterile white suspension. Do not store frozen. Use sterile water or saline solution if administered intramuscularly. Do not use if solution is cloudy or frozen, or if appearance is otherwise unsatisfactory.

**Reagents:**
None.

**Preservatives:**
Contains gentamicin as preservative. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine. Vaccination of pregnant queens should be avoided.

**CONTENTS:**
Cats: 10,000 TCID50 of FPV, 10,000 TCID50 of PCV, and 100,000 TCID50 of FCV. Each of the antigens is formulated in a sterile diluent containing 0.5% sodium chloride and 0.1% polysorbate 80.

**USING THIS PRODUCT:**

Do not use in animals with a known hypersensitivity to any component of the vaccine or in pregnant queens. Do not use in animals with a history of anaphylactic reactions to this vacci-